ATE219495T1 - Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel - Google Patents

Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel

Info

Publication number
ATE219495T1
ATE219495T1 AT96937702T AT96937702T ATE219495T1 AT E219495 T1 ATE219495 T1 AT E219495T1 AT 96937702 T AT96937702 T AT 96937702T AT 96937702 T AT96937702 T AT 96937702T AT E219495 T1 ATE219495 T1 AT E219495T1
Authority
AT
Austria
Prior art keywords
hypocholesterdenic
azetidinone
drugs
usable
sugar substituted
Prior art date
Application number
AT96937702T
Other languages
English (en)
Inventor
Nathan P Yumibe
Kevin B Alton
Heek Margaret Van
Harry R Davis
Wayne D Vaccaro
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26677904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE219495(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE219495T1 publication Critical patent/ATE219495T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96937702T 1995-10-31 1996-10-29 Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel ATE219495T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US818595P 1995-10-31 1995-10-31
US57084795A 1995-12-12 1995-12-12
PCT/US1996/016823 WO1997016455A1 (en) 1995-10-31 1996-10-29 Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents

Publications (1)

Publication Number Publication Date
ATE219495T1 true ATE219495T1 (de) 2002-07-15

Family

ID=26677904

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96937702T ATE219495T1 (de) 1995-10-31 1996-10-29 Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel

Country Status (27)

Country Link
EP (1) EP0877750B1 (de)
JP (2) JP3385031B2 (de)
KR (1) KR100311554B1 (de)
CN (1) CN1103780C (de)
AR (1) AR004701A1 (de)
AT (1) ATE219495T1 (de)
AU (1) AU712158B2 (de)
BR (2) BR9611401B1 (de)
CA (1) CA2235943C (de)
CY (1) CY2353B1 (de)
CZ (1) CZ293957B6 (de)
DE (1) DE69621952T2 (de)
DK (1) DK0877750T3 (de)
ES (1) ES2175141T3 (de)
GE (1) GEP20033006B (de)
HU (1) HU226822B1 (de)
ID (1) ID16177A (de)
IL (1) IL124268A (de)
MX (1) MX9803447A (de)
MY (1) MY114803A (de)
NO (1) NO311692B1 (de)
NZ (1) NZ321766A (de)
PL (1) PL184698B1 (de)
PT (1) PT877750E (de)
SK (1) SK283552B6 (de)
TW (1) TW448181B (de)
WO (1) WO1997016455A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
EP1510521A1 (de) * 2000-12-20 2005-03-02 Schering Corporation Zuckersubstituierte 2-Azetidinone Verwendbar als Hypocholesterdenische Arzneimittel
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
ATE279425T1 (de) * 2000-12-20 2004-10-15 Schering Corp Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel
DE10064398A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Neue Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
IL156550A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
KR20070120617A (ko) * 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
NZ542090A (en) * 2001-01-26 2006-09-29 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
BRPI0208384B1 (pt) 2001-03-28 2016-05-31 Merck Sharp & Dohme síntese enantiosseletiva de compostos intermediários de azetidinona
EP1429756B1 (de) * 2001-09-21 2006-11-22 Schering Corporation Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227506A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1522541A1 (de) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Neue hypocholesterolemische Verbindungen
EP1682117A1 (de) * 2003-10-30 2006-07-26 Merck & Co., Inc. 2-azetidinone als anti-hypercholesterinämische mittel
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US20080194494A1 (en) * 2005-04-26 2008-08-14 Microbia, Inc. 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20080319221A1 (en) 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
CN103102297A (zh) * 2012-09-28 2013-05-15 北京赛林泰医药技术有限公司 一种新的依折麦布的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
CA2120221A1 (en) * 1993-04-23 1994-10-24 Allan W. Rey N-substituted 2-azetidinones
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
NO981950L (no) 1998-06-26
CZ293957B6 (cs) 2004-08-18
PL327987A1 (en) 1999-01-04
KR100311554B1 (ko) 2002-06-20
MX9803447A (es) 1998-09-30
SK283552B6 (sk) 2003-09-11
SK48398A3 (en) 1998-11-04
NZ321766A (en) 1999-07-29
IL124268A (en) 2005-08-31
PT877750E (pt) 2002-09-30
TW448181B (en) 2001-08-01
NO981950D0 (no) 1998-04-29
MY114803A (en) 2003-01-31
CZ129498A3 (cs) 1998-10-14
PL184698B1 (pl) 2002-12-31
HK1012507A1 (en) 1999-08-06
NO311692B1 (no) 2002-01-07
ID16177A (id) 1997-09-11
BR9612998B1 (pt) 2010-03-23
WO1997016455A1 (en) 1997-05-09
GEP20033006B (en) 2003-07-10
DE69621952T2 (de) 2003-01-16
CY2353B1 (en) 2004-06-04
HU226822B1 (en) 2009-11-30
JP3385031B2 (ja) 2003-03-10
CA2235943C (en) 2002-10-01
DE69621952D1 (de) 2002-07-25
EP0877750B1 (de) 2002-06-19
AU7517996A (en) 1997-05-22
HUP9802539A3 (en) 1999-12-28
CN1103780C (zh) 2003-03-26
KR19990067202A (ko) 1999-08-16
AR004701A1 (es) 1999-03-10
CN1205707A (zh) 1999-01-20
JP2001048895A (ja) 2001-02-20
DK0877750T3 (da) 2002-07-15
AU712158B2 (en) 1999-10-28
JPH10512592A (ja) 1998-12-02
HUP9802539A2 (hu) 1998-11-30
ES2175141T3 (es) 2002-11-16
BR9611401B1 (pt) 2010-08-10
CA2235943A1 (en) 1997-05-09
BR9611401A (pt) 1999-01-05
EP0877750A1 (de) 1998-11-18

Similar Documents

Publication Publication Date Title
DE69621952D1 (de) Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
DE69629755D1 (de) Irbesartanhaltiges Arzneimittel
DE69713284D1 (de) Triazol-Derivate als Arzneimittel
NL300214I1 (nl) Chinazolinederivaten.
DE69737936D1 (de) Arzneimittel
IS1903B (is) 2-methýl-thíenó-bensódíasepín, samsetning til inntöku
DE60106489D1 (de) Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel
FI950715A0 (fi) Ytmikromekanisk, symmetrisk tryckskillnadsgivare
TR199600883A2 (tr) Pürin-6-on türevleri.
TR199600715A2 (tr) Kefalosforin türevleri.
NO960499D0 (no) Antineurodegenerativt virksomme 10-aminoalifatyldibenz[b,fÅoksepiner
TR199601012A2 (tr) Sampuan terkibi.
DE69628458D1 (de) 25-hydroxy-16-ene-26,27-bishome-cholecalceriferol derivate
NL1000487C2 (nl) Oogstmachine.
TR199600064A2 (tr) 4-amino-benzoilguanidin-türevleri.
NL1000001A1 (nl) Stal.
ES1032571Y (es) Gafa,
NL1000212C2 (nl) Scharniersysteem.
NL1002934C2 (nl) Deur.
ITTO950598A0 (it) Via tranviaria.
ES1031907Y (es) Parasol perfeccionado.
TR199600311A1 (tr) Pelit sekeri.
ES1030601Y (es) Radiador-convector, perfeccionado.
ES1032115Y (es) Bisagra.
FI953158A0 (fi) Foerfarande foer biologisk rening av vatten, saerskilt foer minskning av kvaevehalten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification